To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
News
A Li2D team has released the peptidomic profile of the virus that causes monkeypox, which they established using tandem mass spectrometry. These data should help to better understand the evolution of the epidemic and allow the creation of targeted tests to potentially detect the threat more quickly and prevent a new epidemic.
A consortium of researchers, including SPI/DMTS metabolomics specialists, presents PeakForest, a database of NMR and mass spectra, which provides storage and annotation services for spectra of reference compounds and metabolic profiles of biological matrices. An open resource to address the evolving needs of the discipline.
A team from SIMoS (DMTS) identifies and characterizes a toxin isolated from black mamba venom, whose specific anticholinergic properties at the type 2 acetylcholine receptor, a regulator of arterial tone, position it as a potential drug candidate for the treatment of cardiovascular diseases.
Timo van Kerkoerle, researcher at NeuroSpin, is one of the 408 winners of the prestigious ERC Starting Grant 2022 call of the European Research Council. Another European success for the Institute.
The QSM4SENIOR project, led by NeuroSpin and the company VENTIO, aims at developing an original early biomarker of aging by using data from the SENIOR study of NeuroSpin. QSM4SENIOR has just been funded by the EOSC-Life.
Deeptope, founded in February 2021 from a technology developed at the DMTS Laboratory of Cellular Immunology and Biotechnology (LICB), is a company of therapeutic antibody engineering that provides antibody optimization and characterization services to biotech or pharmaceutical firms with the goal of increasing the quality of antibodies in a very short timeframe.
Top page
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.